Bimiralisib
Bimiralisib (PI3K-IN-2) is an orally active pan-PI3K and mTOR inhibitor with antineoplastic potential. It induces apoptosis and inhibits proliferation in PI3K/mTOR-hyperactive cancer cells, as demonstrated in various in vitro and in vivo oncology research models targeting this critical survival pathway.
Product Specifications
CAS Number
1225037-39-7
Product Name Alternative
Bimiralisib, 5- (4,6-dimorpholino-1,3,5-triazin-2-yl) -4- (trifluoromethyl) pyridin-2-amine, Mammalian target of Rapamycin, Inhibitor, mTOR, inhibit, S6 Kinase, S6Kinase, Phosphoinositide 3-kinase, pPKB, PQR309, PQR-309, PQR 309, pS6, PI3K, PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, PI3K-IN-2
Field of Research
Signal Transduction
Purity
97.58% (May vary between batches)
Solubility
DMSO:5 mg/mL (12.15 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.43 mM)
Smiles
Nc1cc (c (cn1) -c1nc (nc (n1) N1CCOCC1) N1CCOCC1) C (F) (F) F
Molecular Formula
C17H20F3N7O2
Molecular Weight
411.38
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bs-2409R-Cy5 100 µL
Amphiphysin Polyclonal Antibody, Cy5 Conjugated
Sign In for Pricing
View Details 
orb1004430 100 µL
Guanylyl Cyclase alpha 1 Rabbit Polyclonal Antibody (APC)
Sign In for Pricing
View Details